TP53 status and impact on AML prognosis within the ELN 2022 risk classification
- Author(s)
- Fleming, SA; Tsai, XC; Morris, R; Hou, HA; Wei, AH;
- Details
- Publication Year 2023-08-30,Volume 142,Issue #23,Page 2029-2033
- Journal Title
- Blood
- Abstract
- This study reports 1) frequency of TP53 co-mutation within each component of the ELN 2022 AML risk classification, 2) relevance of TP53 mut VAF<10%, 3) prognostic impact of -7, -5/del(5q), -17/abn(17p), CK/MK or myelodysplasia related gene mutations with/without mutated TP53.
- Publisher
- ASH
- Keywords
- Humans; *Leukemia, Myeloid, Acute/genetics; Mutation; Abnormal Karyotype; *Myelodysplastic Syndromes/genetics; Prognosis; Tumor Suppressor Protein p53/genetics
- Research Division(s)
- Blood Cells And Blood Cancer
- PubMed ID
- 37647854
- Publisher's Version
- https://doi.org/10.1182/blood.2023020855
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-09-07 09:17:07
Last Modified: 2023-12-13 10:19:51